News und Analysen
DGAP-News: EVOTEC UND BRISTOL-MYERS SQUIBB ERWEITEREN IPSC-ALLIANZ
DGAP-News: EVOTEC UND BRISTOL-MYERS SQUIBB ERWEITEREN IPSC-ALLIANZ
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
DGAP-News: EVOTEC NIMMT AN INVESTORENKONFERENZEN TEIL
DGAP-News: EVOTEC NIMMT AN INVESTORENKONFERENZEN TEIL
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein
DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein
DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein
DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein
DGAP-News: First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
DGAP-News: First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL
DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL
DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL
DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL
DGAP-News: First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
DGAP-News: First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc